Literature DB >> 16315065

Elevated plasma concentrations of transforming growth factor-beta 1 in patients with unilateral ureteral obstruction.

Hakan Vuruskan1, Zulkuf Caliskan, Yakup Kordan, Cuneyt Ozakin, Ismet Yavascaoglu, Bulent Oktay.   

Abstract

We measured plasma concentrations of TGF-beta 1 in patients with obstructive ureteral calculi and compared them with the plasma concentrations of healthy volunteers. The present study was a prospective study containing a homogenous group of patients with unilateral ureteral obstruction (UUO). The study consisted of patients with ureteral stones less than 7 mm in diameter that caused mild to moderate obstruction. All patients were referred by the emergency department of our hospital and examined between April 2003 and April 2004. The presence and characteristics of both stone and obstruction were determined by plain abdominal x-ray and gray-scale ultrasonography (US). Blood samples were collected from both patients and control individuals on admission and 1 week after conservative follow-up. The plasma TGF-beta 1 concentration was determined using a quantitative sandwich enzyme immunoassay specific for TGF-beta 1. There were 35 patients with 20 women and 15 men (average age 26.8+/-5.9 years), and 15 volunteers in the control group, with nine women and six men (average age 24.2+/-4.5 years). Average stone size was 5.6 mm+/-1.2 mm (range 3.5-7) for the patient group. US showed the presence of mild hydronephrosis in 24 and moderate hydronephrosis in 11 patients. Plasma concentrations of TGF-beta 1 in patients with ureteral obstruction (1,117+/-5.8 ng/ml, range 36-2,442 ng/ml) were significantly higher than those in the healthy control group (32+/-4 ng/ml) on admission (P<0.001). There was a significant increase in TGF-beta 1 plasma concentrations in the patient group (33,525+/-6.8 ng/ml, range 1,107-73,288 ng/ml) after 1 week follow-up (P<0.001). Ureteral obstruction increases plasma TGF-beta 1 concentrations in patients with ureteral stones as in UUO models in animal studies. A concomitant treatment with an anti-fibrotic agent may reduce the incidence of renal injury during obstruction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16315065     DOI: 10.1007/s00240-005-0509-z

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  32 in total

Review 1.  Recoverability of renal function after relief of chronic partial upper urinary tract obstruction.

Authors:  A A Shokeir; A P Provoost; R J Nijman
Journal:  BJU Int       Date:  1999-01       Impact factor: 5.588

Review 2.  New insights into the consequences and mechanisms of renal impairment in obstructive nephropathy.

Authors:  S Klahr
Journal:  Am J Kidney Dis       Date:  1991-12       Impact factor: 8.860

3.  Urine excretion of transforming growth factor-beta1 in chronic allograft nephropathy.

Authors:  M Boratyńska
Journal:  Ann Transplant       Date:  1999       Impact factor: 1.530

4.  Natural history and current concepts for the treatment of small ureteral calculi.

Authors:  W A Hübner; P Irby; M L Stoller
Journal:  Eur Urol       Date:  1993       Impact factor: 20.096

5.  Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction.

Authors:  Yasunori Mizuguchi; Akira Miyajima; Takeo Kosaka; Takako Asano; Tomohiko Asano; Masamichi Hayakawa
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

Review 6.  Expression, roles, receptors, and regulation of osteopontin in the kidney.

Authors:  Y Xie; M Sakatsume; S Nishi; I Narita; M Arakawa; F Gejyo
Journal:  Kidney Int       Date:  2001-11       Impact factor: 10.612

Review 7.  The emerging role of transforming growth factor-beta in kidney diseases.

Authors:  K Sharma; F N Ziyadeh
Journal:  Am J Physiol       Date:  1994-06

8.  Urinary levels of the renal tubular enzyme N-acetyl-beta-D-glucosaminidase in unilateral obstructive uropathy.

Authors:  M C Carr; C A Peters; A B Retik; J Mandell
Journal:  J Urol       Date:  1994-02       Impact factor: 7.450

9.  Sensitivity of gray scale ultrasound in detecting urinary tract obstruction.

Authors:  P H Ellenbogen; F W Scheible; L B Talner; G R Leopold
Journal:  AJR Am J Roentgenol       Date:  1978-04       Impact factor: 3.959

10.  Macrophages, monocyte chemoattractant peptide-1, and TGF-beta 1 in experimental hydronephrosis.

Authors:  J R Diamond; D Kees-Folts; G Ding; J E Frye; N C Restrepo
Journal:  Am J Physiol       Date:  1994-06
View more
  5 in total

1.  Increased crystal-cell interaction in vitro under co-culture of renal tubular cells and adipocytes by in vitro co-culture paracrine systems simulating metabolic syndrome.

Authors:  Jun Ichikawa; Atsushi Okada; Kazumi Taguchi; Yasuhiro Fujii; Li Zuo; Kazuhiro Niimi; Shuzo Hamamoto; Yasue Kubota; Yukihiro Umemoto; Yasunori Itoh; Takahiro Yasui; Noriyasu Kawai; Keiichi Tozawa; Kenjiro Kohri
Journal:  Urolithiasis       Date:  2013-10-27       Impact factor: 3.436

2.  Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters.

Authors:  Yu-Yan Fan; Akira Nishiyama; Yoshihide Fujisawa; Hiroyuki Kobori; Daisuke Nakano; Junji Matsuura; Naoki Hase; Hirofumi Hitomi; Hideyasu Kiyomoto; Hidenori Urata; Masakazu Kohno
Journal:  J Pharmacol Sci       Date:  2009-08-29       Impact factor: 3.337

3.  The Wnt11 Signaling Pathway in Potential Cellular EMT and Osteochondral Differentiation Progression in Nephrolithiasis Formation.

Authors:  Deng He; Yuchao Lu; Henglong Hu; Jiaqiao Zhang; Baolong Qin; Yufeng Wang; Shuai Xing; Qilin Xi; Shaogang Wang
Journal:  Int J Mol Sci       Date:  2015-07-17       Impact factor: 5.923

Review 4.  Inflammation and EMT: an alliance towards organ fibrosis and cancer progression.

Authors:  Jose Miguel López-Novoa; M Angela Nieto
Journal:  EMBO Mol Med       Date:  2009-09       Impact factor: 12.137

5.  The Effect of Arabic Gum on Renal Function in Reversible Unilateral Ureteric Obstruction.

Authors:  Fayez T Hammad; Suhail Al Salam; Abderrahim Nemmar; Mahmoud Ali; Loay Lubbad
Journal:  Biomolecules       Date:  2019-01-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.